Human natural killer cell deficiencies and susceptibility to infection

Microbes and Infection

Volumn 4, Issue 15, 2002, Pages 1545-1558

  Orange, Jordan S ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Herpesviruses; NK cell deficiency; NK cells; Primary immunodeficiency

Indexed keywords

ADENOSINE DEAMINASE; ALPHA INTERFERON; CD16 ANTIGEN; CD56 ANTIGEN; GAMMA INTERFERON RECEPTOR; HYPOXIA INDUCIBLE FACTOR; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 7; JANUS KINASE; JANUS KINASE 3; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CELL ACTIVATION; CELL FUNCTION; CELL MATURATION; CELL SURVIVAL; CYTOKINE PRODUCTION; CYTOSKELETON; DNA REPAIR; GENE MUTATION; GENETIC POLYMORPHISM; HERPES VIRUS; HERPES VIRUS INFECTION; HUMAN; IMMUNE DEFICIENCY; INFECTION SENSITIVITY; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

COMMUNICABLE DISEASES; GENETIC PREDISPOSITION TO DISEASE; HERPESVIRIDAE; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; KILLER CELLS, NATURAL; MUTATION;

EID: 0036931320     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(02)00038-2     Document Type: Review

References (130)

1. Arase H., Mocarski E.S., Campbell A.E., Hill A.B., Lanier L.L. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science. 296:2002;1323-1326.
2. Mandelboim O., Lieberman N., Lev M., Paul L., Arnon T.I., Bushkin Y., Davis D.M., Strominger J.L., Yewdell J.W., Porgador A. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature. 409:2001;1055-1060.
3. Perussia B. Signaling for cytotoxicity. Nat. Immunol. 1:2000;372-374.
4. Biron C.A., Nguyen K.B., Pien G.C., Cousens L.P., Salazar-Mather T.P. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 17:1999;189-220.
5. Mandelboim O., Malik P., Davis D.M., Jo C.H., Boyson J.E., Strominger J.L. Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc. Natl. Acad. Sci. USA. 96:1999;5640-5644.
6. de Vries E., Koene H.R., Vossen J.M., Gratama J.W., von dem Borne A.E.G.K., Waaijer J.L.M., Haraldsson A., de Haas M., van Tol M.J.D. Identification of an unusual Fc γ receptor IIIa (CD16) on natural killer cells in a patient with recurrent infections. Blood. 88:1996;3022-3027.
7. Jawahar S., Moody C., Chan M., Finberg R., Geha R., Chatila T. Natural killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II). Clin. Exp. Immunol. 103:1996;408-413.
8. Takeuchi T., Nakagawa T., Ikemoto T., Sasaki M., Makino S., Shimizu A., Ohsawa N. A novel mutation in the FcγRIIIA gene (CD16) results in active natural killer cells lacking CD16. Autoimmunity. 31:1999;265-271.
9. Wu J., Edberg J.C., Redecha P.B., Bansal V., Guyre P.M., Coleman K., Salmon J.E., Kimberly R.P. A novel polymorphism of FcγRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J. Clin. Invest. 100:1997;1059-1070.
10. de Haas M., Koene H.R., Kleijer M., de Vries E., Simsek S., van Tol M.J., Roos D., von dem Borne A.E. A triallelic Fc γ receptor type IIIA polymorphism influences the binding of human IgG by NK cell Fc γ RIIIa. J. Immunol. 156:1996;3948-3955.
11. Biron C.A., Byron K.S., Sullivan J.L. Severe herpesvirus infections in an adolescent without natural killer cells. N. Engl. J. M. 320:1989;1731-1735.
12. Wendland T., Herren S., Yawalkar N., Cerny A., Pichler W.J. Strong αβ and γδ TCR response in a patient with disseminated Mycobacterium avium infection and lack of NK cells and monocytopenia. Immunol. Lett. 72:2000;75-82.
13. +subset. J. Allergy Clin. Immunol. 85:1990;453-459.
14. Malejczyk J., Malejczyk M., Majewski S., Orth G., Jablonska S. NK-cell activity in patients with HPV16-associated anogenital tumors: defective recognition of HPV16-harboring keratinocytes and restricted unresponsiveness to immunostimulatory cytokines. Int. J. Cancer. 54:1993;917-921.
15. Akiba H., Motoki Y., Satoh M., Iwatsuki K., Kaneko F. Recalcitrant trichophytic granuloma associated with NK-cell deficiency in a SLE patient treated with corticosteroid. Eur. J. Dermatol. 11:2001;58-62.
16. Fleisher G., Starr S., Koven N., Kamiya H., Douglas S.D., Henle W. A non-X-linked syndrome with susceptibility to severe Epstein-Barr virus infections. J. Pediatr. 100:1982;727-730.
17. Lopez C., Kirkpatrick D., Read S.E., Fitzgerald P.A., Pitt J., Pahwa S., Ching C.Y., Smithwick E.M. Correlation between low natural killing of fibroblasts infected with herpes simplex virus type 1 and susceptibility to herpesvirus infections. J. Infect. Dis. 147:1983;1030-1035.
18. Komiyama A., Kawai H., Yabuhara A., Mitsuhiko Y., Miyagawa Y., Ota M., Hasekura H., Akabane T. Natural killer cell immunodeficiency in siblings: defective killing in the absence of natural killer cytotoxic factor activity in natural killer and lymphokine-activated killer cytotoxicities. Pediatrics. 85:1990;323-330.
19. Buckley R.H., Schiff R.I., Schiff S.E., Markert M.L., Williams L.W., Harville T.O., Roberts J.L., Puck J.M. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J. Pediatr. 130:1997;378-387.
20. Pierce G.F., Polmar S.H., Schacter B.Z., Brovall C., Hornick D.L., Sorensen R.U. Natural cytotoxicity in immunodeficiency diseases: preservation of natural killer activity and the in vivo appearance of radioresistant killing. Hum. Immunol. 15:1986;85-96.
21. Lopez C., Kirkpatrick D., Fitzgerald P.A., Ching C.Y., Pahwa R.N., Good R.A., Smithwick E.M. Studies of the cell lineage of the effector cells that spontaneously lyse HSV-1 infected fibroblasts (NK(HSV-1)). J. Immunol. 129:1982;824-828.
22. Koren H.S., Amos D.B., Buckley R.H. Natural killing in immunodeficient patients. J. Immunol. 120:1978;796-799.
23. Sanal S.O., Buckley R.H. Antibody-dependent cellular cytotoxicity in primary immunodeficiency diseases and with normal leukocyte subpopulations. Importance of the type of target. J. Clin. Invest. 61:1978;1-10.
24. Flomenberg N., Welte K., Mertelsmann R., O'Reilly R., Dupont B. Interleukin 2-dependent natural killer (NK) cell lines from patients with primary T cell immunodeficiencies. J. Immunol. 130:1983;2635-2643.
25. Sirianni M.C., Businco L., Seminara R., Aiuti F. Severe combined immunodeficiencies, primary T-cell defects and DiGeorge syndrome in humans: characterization by monoclonal antibodies and natural killer cell activity. Clin. Immunol. Immunopathol. 28:1983;361-370.
26. Lipinski M., Virelizier J.L., Tursz T., Griscelli C. Natural killer and killer cell activities in patients with primary immunodeficiencies or defects in immune interferon production. Eur. J. Immunol. 10:1980;246-249.
27. Peter H.H., Friedrich W., Dopfer R., Muller W., Kortmann C., Pichler W.J., Heinz F., Rieger C.H. NK cell function in severe combined immunodeficiency (SCID): evidence of a common T and NK cell defect in some but not all SCID patients. J. Immunol. 131:1983;2332-2339.
28. Candotti F., Oakes S.A., Johnston J.A., Giliani S., Schumacher R.F., Mella P., Fiorini M., Ugazio A.G., Badolato R., Notarangelo L.D., Bozzi F., Macchi P., Strina D., Vezzoni P., Blaese R.M., O'Shea J.J., Villa A. Structural and functional basis for JAK3-deficient severe combined immunodeficiency. Blood. 90:1997;3996-4003.
29. Kumaki S., Ishii N., Minegishi M., Tsuchiya S., Cosman D., Sugamura K., Konno T. Functional role of interleukin-4 (IL-4) and IL-7 in the development of X-linked severe combined immunodeficiency. Blood. 93:1999;607-612.
30. Notarangelo L.D., Giliani S., Mazza C., Mella P., Savoldi G., Rodriguez-Perez C., Mazzolari E., Fiorini M., Duse M., Plebani A., Ugazio A.G., Vihinen M., Candotti F., Schumacher R.F. Of genes and phenotypes: the immunological and molecular spectrum of combined immune deficiency. Defects of the gamma(c)-JAK3 signaling pathway as a model. Immunol. Rev. 178:2000;39-48.
31. Ghaffar F., Carrick K., Rogers B.B., Margraf L.R., Krisher K., Ramilo O. Disseminated infection with varicella-zoster virus vaccine strain presenting as hepatitis in a child with adenosine deaminase deficiency. Pediatr. Infect. Dis. J. 19:2000;764-766.
32. Norris P.G., Limb G.A., Hamblin A.S., Hawk J.L. Impairment of natural-killer-cell activity in xeroderma pigmentosum. N. Engl. J. M. 319:1988;1668-1669.
33. Norris P.G., Limb G.A., Hamblin A.S., Lehmann A.R., Arlett C.F., Cole J., Waugh A.P., Hawk J.L. Immune function, mutant frequency, and cancer risk in the DNA repair defective genodermatoses xeroderma pigmentosum, Cockayne's syndrome, and trichothiodystrophy. J. Invest. Dermatol. 94:1990;94-100.
34. Ueno Y., Miyawaki T., Seki H., Hara K., Sato T., Taniguchi N., Takahashi H., Kondo N. Impaired natural killer cell activity in Bloom's syndrome could be restored by human recombinant IL-2 in vitro. Clin. Immunol. Immunopathol. 35:1985;226-233.
35. Etzioni A., Lahat N., Benderly A., Katz R., Pollack S. Humoral and cellular immune dysfunction in a patient with Bloom's syndrome and recurrent infections. J. Clin. Lab. Immunol. 28:1989;151-154.
36. Hersey P., Edwards A., Lewis R., Kemp A., McInnes J. Deficient natural killer cell activity in a patient with Fanconi's anaemia and squamous cell carcinoma. Association with defect in interferon release. Clin. Exp. Immunol. 48:1982;205-212.
37. Froom P., Aghai E., Dobinsky J.B., Quitt M., Lahat N. Reduced natural killer activity in patients with Fanconi's anemia and in family members. Leukoc. Res. 11:1987;197-199.
38. Tsuge I., Matsuoka H., Torii S., Okada J., Mizuno T., Matsuoka M., Kodera Y., Takahashi T. Preservation of natural killer and interleukin-2 activated killer cell activity in ataxia-telangiectasia with T cell deficiency. J. Clin. Lab. Immunol. 23:1987;7-13.
39. Zimmer J., Donato L., Hanau D., Cazenave J.P., Tongio M.M., Moretta A., de la Salle H. Activity and phenotype of natural killer cells in peptide transporter (TAP)-deficient patients (type I bare lymphocyte syndrome). J. Exp. M. 187:1998;117-122.
40. Vitale M., Zimmer J., Castriconi R., Hanau D., Donato L., Bottino C., Moretta L., de la Salle H., Moretta A. Analysis of natural killer cells in TAP2-deficient patients: expression of functional triggering receptors and evidence for the existence of inhibitory receptor(s) that prevent lysis of normal autologous cells. Blood. 99:2002;1723-1729.
41. Furukawa H., Yabe T., Watanabe K., Miyamoto R., Miki A., Akaza T., Tadokoro K., Tohma S., Inoue T., Yamamoto K., Juji T. Tolerance of NK and LAK activity for HLA class I-deficient targets in a TAP1-deficient patient (bare lymphocyte syndrome type I). Hum. Immunol. 60:1999;32-40.
42. Perez N., Virelizier J.L., Arenzana-Sieisdedos F., Fischer A., Griscelli C. Impaired natural killer activity in lymphohistiocytosis syndrome. J. Pediatr. 104:1984;569-573.
43. Imashuku S., Shigeyoshi H., Todo S. Hemophagocytic lymphohistiocytosis in infancy and childhood. J. Pediatr. 130:1997;352-357.
44. Stark B., Cohen I.J., Pecht M., Umiel T., Apte R.N., Friedman E., Levin S., Vogel R., Schlesinger M., Zaizov R. Immunologic dysregulation in a patient with familial hemophagocytic lymphohistiocytosis. Cancer. 60:1987;2629-2636.
45. Arico M., Nespoli L., Maccario R., Montagna D., Bonetti F., Caselli D., Burgio G.R. Natural cytotoxicity impairment in familial haemophagocytic lymphohistiocytosis. Arch. Dis. Child. 63:1988;292-296.
46. Eife R., Janka G.E., Belohradsky B.H., Holtmann H. Natural killer cell function and interferon production in familial hemophagocytic lymphohistiocytosis. Pediatr. Hematol. Oncol. 6:1989;265-272.
47. Kataoka Y., Todo S., Morioka Y., Sugie K., Nakamura Y., Yodoi J., Imashuku S. Impaired natural killer activity and expression of interleukin-2 receptor antigen in familial erythrophagocytic lymphohistiocytosis. Cancer. 65:1990;1937-1941.
48. Sullivan K.E., DeLaat C.A., Douglas S.D., Filipovich A.H. Defective natural killer cell function in patients with hemophagocytic lymphohistiocytosis and first degree relatives. Pediatr. Res. 44:1998;465-468.
49. Osugi Y., Hara J., Tagawa S., Takai K., Hosoi G., Matsuda Y., Ohta H., Fujisaki H., Kobayashi M., Sakata N., Kawa-Ha K., Shintaro O., Tawa A. Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood. 89:1997;4100-4103.
50. Henter J.I., Elinder G., Soder O., Hansson M., Andersson B., Andersson U. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood. 78:1991;2918-2922.
51. Akashi K., Hayashi S., Gondo H., Mizuno S.I., Harada M., Tamura K., Yamasaki K., Shibuya T., Uike N., Okamura T., Miyamoto T., Niho Y. Involvement of interferon-γ and macrophage colony-stimulating factor in pathogenesis of haemophagocytic lymphohistiocytosis in adults. Br. J. Haematol. 87:1994;243-250.
52. Stepp S.E., Dufourcq-Lagelouse R., Le Deist F., Bhawan S., Certain S., Mathew P.A., Henter J.I., Bennett M., Fischer A., de Saint Basile G., Kumar V. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 286:1999;1957-1959.
53. Goransdotter Ericson K., Fadeel B., Nilsson-Ardnor S., Soderhall C., Samuelsson A., Janka G., Schneider M., Gurgey A., Yalman N., Revesz T., Egeler R., Jahnukainen K., Storm-Mathiesen I., Haraldsson A., Poole J., de Saint Basile G., Nordenskjold M., Henter J. Spectrum of perforin gene mutations in familial hemophagocytic lymphohistiocytosis. Am. J. Hum. Genet. 68:2001;590-597.
54. Kogawa K., Lee S.M., Villanueva J., Marmer D., Sumegi J., Filipovich A.H. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood. 99:2002;61-66.
55. Roder J.C., Haliotis T., Klein M., Korec S., Jett J.R., Ortaldo J., Heberman R.B., Katz P., Fauci A.S. A new immunodeficiency disorder in humans involving NK cells. Nature. 284:1980;553-555.
56. Haliotis T., Roder J., Klein M., Ortaldo J., Fauci A.S., Herberman R.B. Chediak-Higashi gene in humans I. Impairment of natural-killer function. J. Exp. M. 151:1980;1039-1048.
57. Klein M., Roder J., Haliotis T., Korec S., Jett J.R., Herberman R.B., Katz P., Fauci A.S. Chediak-Higashi gene in humans. II. The selectivity of the defect in natural-killer and antibody-dependent cell-mediated cytotoxicity function. J. Exp. M. 151:1980;1049-1058.
58. Roder J.C., Haliotis T., Laing L., Kozbor D., Rubin P., Pross H., Boxer L.A., White J.G., Fauci A.S., Mostowski H., Matheson D.S. Further studies of natural killer cell function in Chediak-Higashi patients. Immunology. 46:1982;555-560.
59. +) cells in Chediak-Higashi patients are present in normal numbers but are abnormal in function and morphology. J. Clin. Invest. 70:1982;193-197.
60. Katz P., Zaytoun A.M., Fauci A.S. Deficiency of active natural killer cells in the Chediak-Higashi syndrome. Localization of the defect using a single cell cytotoxicity assay. J. Clin. Invest. 69:1982;1231-1238.
61. Brahmi Z. Nature of natural killer cell hyporesponsiveness in the Chediak-Higashi syndrome. Hum. Immunol. 6:1983;45-52.
62. Targan S.R., Oseas R. The "lazy" NK cells of Chediak-Higashi syndrome. J. Immunol. 130:1983;2671-2674.
63. Rubin C.M., Burke B.A., McKenna R.W., McClain K.L., White J.G., Nesbit M.E.J., Filipovich A.H. The accelerated phase of Chediak-Higashi Syndrome. Cancer. 56:1985;524-530.
64. Bejaoui M., Veber F., Girault D., Gaud C., Blanche S., Griscelli C., Fischer A. Phase accélérée de la maladie de Chediak-Higashi. Arch. Fr. Pediatr. 46:1989;733-736.
65. Barbosa M.D., Nguyen Q.A., Tchernev V.T., Ashley J.A., Detter J.C., Blaydes S.M., Brandt S.J., Chotai D., Hodgman C., Solari R.C., Lovett M., Kingsmore S.F. Identification of the homologous beige and Chediak-Higashi syndrome genes. Nature. 382:1996;262-265.
66. Burkhardt J.K., Wiebel F.A., Hester S., Argon Y. The giant organelles in beige and Chediak-Higashi fibroblasts are derived from late endosomes and mature lysosomes. J. Exp. M. 178:1993;1845-1856.
67. Klein C., Philippe N., Le Deist F., Fraitag S., Prost C., Durandy A., Fischer A., Griscelli C. Partial albinism with immunodeficiency (Griscelli syndrome). J. Pediatr. 125:1994;886-895.
68. Mancini A.J., Chan L.S., Paller A.S. Partial albinism with immunodeficiency: Griscelli syndrome: report of a case and review of the literature. J. Am. Acad. Dermatol. 38:1998;295-300.
69. Plebani A., Ciravegna B., Ponte M., Mingari M.C., Moretta L. Interleukin-2 mediated restoration of natural killer cell function in a patient with Griscelli syndrome. Eur. J. Pediatr. 159:2000;713-714.
70. Pastural E., Barrat F.J., Dufourcq-Lagelouse R., Certain S., Sanal O., Jabado N., Seger R., Griscelli C., Fischer A., de Saint Basile G. Griscelli disease maps to chromosome 15q21 and is associated with mutations in the myosin-Va gene. Nat. Genet. 16:1997;289-292.
71. Menasche G., Pastural E., Feldmann J., Certain S., Ersoy F., Dupuis S., Wulffraat N., Bianchi D., Fischer A., Le Deist F., de Saint Basile G. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat. Genet. 25:2000;173-176.
72. Sullivan J.L., Byron K.S., Brewster F.E., Purtilo D.T. Deficient natural killer cell activity in X-linked lymphoproliferative syndrome. Science. 210:1980;543-545.
73. Lindsten T., Seeley J.K., Ballow M., Sakamoto K., St Onge S., Yetz J., Aman P., Purtilo D.T. Immune deficiency in the X-linked lymphoproliferative syndrome. II. Immunoregulatory T cell defects. J. Immunol. 129:1982;2536-2540.
74. Harada S., Bechtold T., Seeley J.K., Purtilo D.T. Cell-mediated immunity to Epstein-Barr virus (EBV) and natural killer (NK)-cell activity in the X-linked lymphoproliferative syndrome. Int. J. Cancer. 30:1982;739-744.
75. Argov S., Johnson D.R., Collins M., Koren H.S., Lipscomb H., Purtilo D.T. Defective natural killing activity but retention of lymphocyte-mediated antibody-dependent cellular cytotoxicity in patients with the X-linked lymphoproliferative syndrome. Cell. Immunol. 100:1986;1-9.
76. Benoit L., Wang X., Pabst H.F., Dutz J., Tan R. Defective NK cell activation in X-linked lymphoproliferative disease. J. Immunol. 165:2000;3549-3553.
77. Tangye S.G., Phillips J.H., Lanier L.L., Nichols K.E. Functional requirement for SAP in 2B4-mediated activation of human natural killer cells as revealed by the X-linked lymphoproliferative syndrome. J. Immunol. 165:2000;2932-2936.
78. Parolini S., Bottino C., Falco M., Augugliaro R., Giliani S., Franceschini R., Ochs H.D., Wolf H., Bonnefoy J.Y., Biassoni R., Moretta L., Notarangelo L.D., Moretta A. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J. Exp. M. 192:2000;337-346.
79. Sayos J., Wu C., Morra M., Wang N., Zhang X., Allen D., van Schaik S., Notarangelo L., Geha R., Roncarolo M.G., Oettgen H., De Vries J.E., Aversa G., Terhorst C. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature. 395:1998;462-469.
80. Nakajima H., Cella M., Langen H., Friedlein A., Colonna M. Activating interactions in human NK cell recognition: the role of 2B4-CD48. Eur. J. Immunol. 29:1999;1676-1683.
81. Anderson D.C., Schmalsteig F.C., Finegold M.J., Hughes B.J., Rothlein R., Miller L.J., Kohl S., Tosi M.F., Jacobs R.L., Waldrop T.C., et al. The severe and moderate phenotypes of heritable Mac-1, LFA-1 deficiency: their quantitative definition and relation to leukocyte dysfunction and clinical features. J. Infect. Dis. 152:1985;668-689.
82. Lau Y.L., Low L.C., Jones B.M., Lawton J.W. Defective neutrophil and lymphocyte function in leucocyte adhesion deficiency. Clin. Exp. Immunol. 85:1991;202-208.
83. Kohl S., Springer T.A., Schmalstieg F.C., Loo L.S., Anderson D.C. Defective natural killer cytotoxicity and polymorphonuclear leukocyte antibody-dependent cellular cytotoxicity in patients with LFA-1/OKM-1 deficiency. J. Immunol. 133:1984;2972-2978.
84. Anderson D.C., Schmalstieg F.C., Shearer W., Becker-Freeman K., Kohl S., Smith C.W., Tosi M.F., Springer T. Leukocyte LFA-1, OKM1, p150, 95 deficiency syndrome: functional and biosynthetic studies of three kindreds. Fed. Proc. 44:1985;2671-2677.
85. Kohl S., Loo L.S., Schmalstieg F.S., Anderson D.C. The genetic deficiency of leukocyte surface glycoprotein Mac-1, LFA-1, p150, 95 in humans is associated with defective antibody-dependent cellular cytotoxicity in vitro and defective protection against herpes simplex virus infection in vivo. J. Immunol. 137:1986;1688-1694.
86. Ross G.D., Thompson R.A., Walport M.J., Springer T.A., Watson J.V., Ward R.H., Lida J., Newman S.L., Harrison R.A., Lachmann P.J. Characterization of patients with an increased susceptibility to bacterial infections and a genetic deficiency of leukocyte membrane complement receptor type 3 and the related membrane antigen LFA-1. Blood. 66:1985;882-890.
87. Krensky A.M., Mentzer S.J., Clayberger C., Anderson D.C., Schmalstieg F.C., Burakoff S.J., Springer T.A. Heritable lymphocyte function-associated antigen-1 deficiency: abnormalities of cytotoxicity and proliferation associated with abnormal expression of LFA-1. J. Immunol. 135:1985;3102-3108.
88. Kishimoto T.K., Hollander N., Roberts T.M., Anderson D.C., Springer T.A. Heterogeneous mutations in the beta subunit common to the LFA-1, Mac-1, and p150, 95 glycoproteins cause leukocyte adhesion deficiency. Cell. 50:1987;193-202.
89. Shibuya K., Lanier L.L., Phillips J.H., Ochs H.D., Shimizu K., Nakayama E., Nakauchi H., Shibuya A. Physical and functional association of LFA-1 with DNAM-1 adhesion molecule. Immunity. 11:1999;615-623.
90. Ostenstad B., Giliani S., Mellbye O.J., Nilsen B.R., Abrahamsen T. A boy with X-linked hyper-IgM syndrome and natural killer cell deficiency. Clin. Exp. Immunol. 107:1997;230-234.
91. Amakata Y., Fujiyama Y., Andoh A., Hodohara K., Bamba T. Mechanism of NK cell activation induced by coculture with dendritic cells derived from peripheral blood monocytes. Clin. Exp. Immunol. 124:2001;214-222.
92. Carbone E., Ruggiero G., Terrazzano G., Palomba C., Manzo C., Fontana S., Spits H., Karre K., Zappacosta S. A new mechanism of NK cell cytotoxicity activation: the CD40-CD40 ligand interaction. J. Exp. M. 185:1997;2053-2060.
93. Ware R.E., Hall S.E., Rosse W.F. Paroxysmal nocturnal hemoglobinuria with onset in childhood and adolescence. N. Engl. J. M. 325:1991;991-996.
94. Yoda Y., Abe T. Deficient natural killer (NK) cells in paroxysmal nocturnal haemoglobinuria (PNH): studies of lymphoid cells fractionated by discontinuous density gradient centrifugation. Br. J. Haematol. 60:1985;669-675.
95. Richards S.J., Norfolk D.R., Swirsky D.M., Hillmen P. Lymphocyte subset analysis and glycosylphosphatidylinositol phenotype in patients with paroxysmal nocturnal hemoglobinuria. Blood. 92:1998;1799-1806.
96. Yoda Y., Abe T., Mitamura K., Saito K., Kawada K., Onozawa Y., Adachi Y., Nomura T. Deficient natural killer (NK) cell activity in paroxysmal nocturnal haemoglobinuria (PNH). Br. J. Haematol. 52:1982;559-562.
97. De Souza M.H., Pires A.R., Diamond H.R. Study of lymphocyte populations and natural killer activity in severe aplastic anaemia. J. Clin. Lab. Immunol. 30:1989;111-116.
98. Takeda J., Miyata T., Kawagoe K., Iida Y., Endo Y., Fujita T., Takahashi M., Kitani T., Kinoshita T. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 73:1993;703-711.
99. Schubert J., Schmidt R.E., Medof M.E. Regulation of glycoinositol phospholipid anchor assembly in human lymphocytes. Absent mannolipid synthesis in affected T and natural killer cell lines from paroxysmal nocturnal hemoglobinuria patients. J. Biol. Chem. 268:1993;6281-6287.
100. Klaassen R.J., Ouwehand W.H., Huizinga T.W., Engelfriet C.P., von dem Borne A.E. The Fc-receptor III of cultured human monocytes. Structural similarity with FcRIII of natural killer cells and role in the extracellular lysis of sensitized erythrocytes. J. Immunol. 144:1990;599-606.
101. Ortaldo J.R., Glenn G.M., Young H.A., Frey J.L. Natural killer (NK) cell lytic dysfunction and putative NK cell receptor expression abnormality in members of a family with chromosome 3p-linked von Hippel-Lindau disease. J. Natl. Cancer. Inst. 84:1992;1897-1903.
102. Anderson S.K., Gallinger S., Roder J., Frey J., Young H.A., Ortaldo J.R. A cyclophilin-related protein involved in the function of natural killer cells. Proc. Natl. Acad. Sci. USA. 90:1993;542-546.
103. Frey J.L., Bino T., Kantor R.R., Segal D.M., Giardina S.L., Roder J., Anderson S., Ortaldo J.R. Mechanism of target cell recognition by natural killer cells: characterization of a novel triggering molecule restricted to CD3- large granular lymphocytes. J. Exp. M. 174:1991;1527-1536.
104. Wade N.A., Lepow M.L., Veazey J., Meuwissen H.J. Progressive varicella in three patients with Wiskott-Aldrich syndrome: treatment with adenine arabinoside. Pediatrics. 75:1985;672-675.
105. Sullivan K.E., Mullen C.A., Blaese R.M., Winkelstein J.A. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J. Pediatr. 125:1994;876-885.
106. Messina C., Kirkpatrick D., Fitzgerald P.A., O'Reilly R.J., Siegal F.P., Cunningham-Rundles C., Blaese M., Oleske J., Pahwa S., Lopez C. Natural killer cell function and interferon generation in patients with primary immunodeficiencies. Clin. Immunol. Immunopathol. 39:1986;394-404.
107. Plebani A., Airo P., Brugnoni D., Lebowitz M., Cattaneo R., Monafo V., Meini A., Notarangelo L.D., Duse M., Ugazio A.G. Expansion of large granular lymphocyte subsets in Wiskott-Aldrich syndrome. Haematologica. 80:1995;521-525.
108. Orange J.S., Ramesh N., Remold-O'Donnell E., Sasahara Y., Koopman L., Byrne M., Bonilla F.A., Rosen F.S., Geha R.S., Strominger J.L. Wiskott-Aldrich Syndrome protein is required for NK cell cytotoxicity and localizes to NK cell activating immunologic synapses. Proc. Natl. Acad. Sci. USA. 99:2002;11351-11356.
109. Dorman S.E., Uzel G., Roesler J., Bradley J.S., Bastian J., Billman G., King S., Filie A., Schermerhorn J., Holland S.M. Viral infections in interferon-γ receptor deficiency. J. Pediatr. 135:1999;640-643.
110. Altare F., Lammas D., Revy P., Jouanguy E., Doffinger R., Lamhamedi S., Drysdale P., Scheel-Toellner D., Girdlestone J., Darbyshire P., Wadhwa M., Dockrell H., Salmon M., Fischer A., Durandy A., Casanova J.L., Kumararatne D.S. Inherited interleukin 12 deficiency in a child with bacille Calmette-Guérin and Salmonella enteritidis disseminated infection. J. Clin. Invest. 102:1998;2035-2040.
111. Dorman S.E., Holland S.M. Mutation in the signal-transducing chain of the interferon-γ receptor and susceptibility to mycobacterial infection. J. Clin. Invest. 101:1998;2364-2369.
112. Altare F., Durandy A., Lammas D., Emile J.F., Lamhamedi S., Le Deist F., Drysdale P., Jouanguy E., Doffinger R., Bernaudin F., Jeppsson O., Gollob J.A., Meinl E., Segal A.W., Fischer A., Kumararatne D., Casanova J.L. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science. 280:1998;1432-1435.
113. de Jong R., Altare F., Haagen I.A., Elferink D.G., Boer T., van Breda Vriesman P.J., Kabel P.J., Draaisma J.M., van Dissel J.T., Kroon F.P., Casanova J.L., Ottenhoff T.H. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science. 280:1998;1435-1438.
114. Aspalter R.M., Sewell W.A., Dolman K., Farrant J., Webster A.D. Deficiency in circulating natural killer (NK) cell subsets in common variable immunodeficiency and X-linked agammaglobulinaemia. Clin. Exp. Immunol. 121:2000;506-514.
115. Pross H.F., Gupta S., Good R.A., Baines M.G. Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. VII. The effect of immunodeficiency disease. Cell. Immunol. 43:1979;160-175.
116. Vyas Y.M., Mehta K.M., Morgan M., Maniar H., Butros L., Jung S., Burkhardt J.K., Dupont B. Spatial organization of signal transduction molecules in the NK cell immune synapses during MHC class I-regulated noncytolytic and cytolytic interactions. J. Immunol. 167:2001;4358-4367.
117. Zonana J., Elder M.E., Schneider L.C., Orlow S.J., Moss C., Golabi M., Shapira S.K., Farndon P.A., Wara D.W., Emmal S.A., Ferguson B.M. A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-γ (NEMO). Am. J. Hum. Genet. 67:2000;1555-1562.
118. Doffinger R., Smahi A., Bessia C., Geissmann F., Feinberg J., Durandy A., Bodemer C., Kenwrick S., Dupuis-Girod S., Blanche S., Wood P., Rabia S.H., Headon D.J., Overbeek P.A., Le Deist F., Holland S.M., Belani K., Kumararatne D.S., Fischer A., Shapiro R., Conley M.E., Reimund E., Kalhoff H., Abinun M., Munnich A., Israel A., Courtois G., Casanova J.L. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-κB signaling. Nat. Genet. 27:2001;277-285.
119. Jain A., Ma C.A., Liu S., Brown M., Cohen J., Strober W. Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohidrotic ectodermal dysplasia. Nat. Immunol. 2:2001;223-228.
120. Orange J.S., Brodeur S.R., Jain A., Bonilla F.A., Schneider L.C., Kretschmer R., Nurko S., Rasmussen W.L., Kohler J.R., Gellis S.E., Ferguson B.M., Strominger J.L., Zonana J., Ramesh N., Ballas Z.K., Geha R. Deficient natural killer cell cytotoxicity in patients with IKK-γ/NEMO mutations. J. Clin. Invest. 109:2002;1501-1509.
121. Valle Blazquez M., Luque I., Collantes E., Aranda E., Solana R., Pena J., Munoz E. Cellular redox status influences both cytotoxic and NF-κ B activation in natural killer cells. Immunology. 90:1997;455-460.
122. Whiteside T.L., Friberg D. Natural killer cells and natural killer cell activity in chronic fatigue syndrome. Am. J. M. 105:1998;27S-34S.
123. Levine P.H., Whiteside T.L., Friberg D., Bryant J., Colclough G., Herberman R.B. Dysfunction of natural killer activity in a family with chronic fatigue syndrome. Clin. Immunol. Immunopathol. 88:1998;96-104.
124. Witte T., Werwitzke S., Schmidt R.E. CMV complications in common variable immunodeficiency. Immunobiology. 202:2000;194-198.
125. Cambronero R., Sewell W.A., North M.E., Webster A.D., Farrant J. Up-regulation of IL-12 in monocytes: a fundamental defect in common variable immunodeficiency. J. Immunol. 164:2000;488-494.
126. Scaringi L., Rosati E., Cornacchione P., Fettucciari K., Sabatini R., Biondi R., Mezzasoma L., Valiani M., D'Errico P., Marconi P. Local and systemic immune response to inactivated Candida albicans in mice. Nat. Immun. 14:1995;234-249.
127. Gulay Z., Imir T. Anti-candidial activity of natural killer (NK) and lymphokine activated killer (LAK) lymphocytes in vitro. Immunobiology. 195:1996;220-230.
128. Palma-Carlos A.G., Palma-Carlos M.L. Chronic mucocutaneous candidiasis revisited. Allerg. Immunol. (Paris). 33:2001;229-232.
129. Guduri S., Ballas Z.K. Deficient NK-cell function in adult patients with recurrent non-invasive mucosal candidiasis. J. Allergy Clin. Immunol. 109:2002;S186.
130. Segura T., Ballas Z.K. Natural Killer (NK) cell deficiency in a patient with chronic mucocutaneous candidiasis. J. Allergy Clin. Immunol. 101:1998;313.